Enterococci, a part of normal gut flora, are not particularly pathogenic organisms in humans. For example, they do not cause respiratory tract infections. The most frequent enterococcal infections are urinary tract infections. Despite their lack of pathogenicity, enterococci have emerged as significant nosocomial pathogens in the United States and elsewhere. Enterococci are formidable pathogens because of their resistance to antimicrobial agents. Enterococci are intrinsically resistant to b-lactam agents and aminoglycosides and were the first bacteria to acquire vancomycin resistance. Infection control measures have been far from effective at preventing the dissemination of vancomycinresistant enterococci in the hospital. Therapy for infections due to vancomycin-resistant enterococci presents real challenges. Most isolates remain susceptible to nitrofurantoin, but this agent is useful only for urinary tract infections. The greatest threat posed by vancomycin-resistant enterococci is the potential to transfer their resistance genes to more pathogenic gram-positive bacteria, which could produce truly frightening pathogens.
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There has been a great deal of concern in recent years about
No one is exactly certain why enterococci were the first to develop vancomycin resistance, but two facts might have the growing menace of antimicrobial-resistant organisms [1] . Bacteria and other microorganisms have shown a remarkable played a role: enterococci are part of normal gut flora, and the emergence of vancomycin resistance was associated with ability to develop resistance to virtually every antimicrobial agent developed for therapeutic use in humans and animals.
increasing use of oral vancomycin for the treatment of documented and presumed Clostridium difficile enterocolitis. InArguably, the most impressive accomplishment of bacteria to date in this arena has been the development of vancomycin creasing use of parenteral vancomycin for the treatment of intravascular device -related infections might also have been resistance in enterococci.
This achievement is impressive for a number of reasons. important [4] . The agricultural use of the related glycopeptide avoparcin may have played a role in Europe, but this drug has First, many infectious disease experts thought that it would be virtually impossible for intrinsically susceptible organisms to not been used in the United States. In any case, enterococci were the first to acquire vancomycin resistance, and as a result, develop vancomycin resistance. This impossibility was based in part on the fact that vancomycin had been in clinical use vancomycin resistance is now causing significant problems in Europe and especially in the United States. for ú35 years without any emergence of resistance. Furthermore, the mechanism of action of vancomycin is such that it would require a major alteration in bacterial cell wall synthesis Enterococcal Infections to develop resistance unless the organisms could find a way to inactivate or ''detoxify'' vancomycin, which seemed highly Enterococci, as noted above, are normal inhabitants of the unlikely.
intestinal tract of humans and animals. More than a dozen Thus, it was with considerable surprise and great concern species of enterococci are currently recognized [5] . Of these, that the first reports of the occurrence of vancomycin-resistant two species, Enterococcus faecalis and Enterococcus faecium, enterococci in Europe began to appear in the mid 1980s [2] .
are the most important causes of enterococcal infections in Moreover, once scientists elucidated the mechanism by which humans. About 85% to 90% of enterococcal infections in huthis resistance was made possible, it was realized that it took mans are caused by E. faecalis, with another 5% to 10% caused an incredibly complex set of genetic developments to enable by E. faecium [5] . The relative frequency of enterococcal infecenterococci to become resistant [3] .
tions has shifted somewhat, however, and as E. faecium has become increasingly resistant to antimicrobial agents, it has emerged as a major nosocomial pathogen [5] . The development of vancomycin resistance in enterococci September 1996 in New Orleans.
represents a classic ''bad news, good news'' scenario. The tory tract in humans, and they do not cause primary cellulitis. in Europe and subsequently in the United States in the mid and late 1980s [5] . Unlike Streptococcus pyogenes and Staphylococcus aureus, enterococci do not possess enzymes that allow tissue spread and invasion. Enterococci do not produce potent exotoxins.
Genetics of Vancomycin-Resistant Enterococci
The most frequent infections caused by enterococci are urinary tract infections. The second most frequent infections are
The initial observations of vancomycin-resistant strains reintraabdominal and pelvic sepsis and surgical wound infections, vealed the presence of several different phenotypes of glycoin which enterococci are almost always part of a mixed flora peptide resistance. The so-called vanA resistance phenotype, of colonic organisms. The third most frequent infections are which is the most frequently encountered, consists of highbacteremias, including both primary bacteremias that are prelevel vancomycin resistance that is also accompanied by highsumably from a source in the gastrointestinal tract and bacterlevel resistance to teicoplanin [3] . Vancomycin resistance in emias that are secondary to urinary tract and intraabdominal these strains is vancomycin-and/or teicoplanin-inducible. The infections or the use of intravascular devices.
genes encoding vancomycin resistance are often found on a Although enterococcal endocarditis is relatively rare, it is transposon that is relatively easily transferred to other enterodifficult to treat because of the relative resistance of enterococci coccal species by conjugation [3, 10] . to antimicrobial agents. Meningitis represents an even rarer but
Vancomycin-resistant enterococci with the vanB resistance potentially serious infection caused by enterococci [5] .
phenotype have variable levels of vancomycin resistance and Despite their relative lack of pathogenicity, enterococci have are susceptible to teicoplanin. The vanB resistance phenotype emerged as significant nosocomial pathogens in the United is also inducible by vancomycin, but not by teicoplanin, and States and elsewhere. According to recent National Nosocomial exposure to vancomycin also produces teicoplanin resistance. Infections Surveillance surveys in the United States, entero-
The genes encoding the vanB resistance phenotype are more cocci currently rank second or third, depending on the year, as commonly chromosomal but can also be transferred by conjucauses of infections due to various organisms [6] . This result gation [10, 11] . is particularly impressive, in view of the fact that enterococci
The vanC resistance phenotype, which consists of relatively are not a significant cause of nosocomial respiratory tract infeclow levels of vancomycin resistance without teicoplanin resistions.
tance, is caused by chromosomally encoded genes that are found in all strains of Enterococcus casseliflavus, Enterococcus gallinarum, and Enterococcus flavescens. These genes are not Antimicrobial Resistance in Enterococci transferable. Recently, Perichon and co-workers [12] described a fourth phenotype, vanD, that is similar to vanB (vancomycin The characteristic of enterococci that makes them such for-MIC, 64 mg/mL; teicoplanin MIC, 4 mg/mL) and has thus far midable pathogens is their resistance to antimicrobial agents.
been noted only in a rare strain of E. faecium. All enterococci are intrinsically resistant to a number of antimi-
The genetic basis for vancomycin resistance is remarkably crobial agents [7] . Thus, they exhibit low levels of resistance to complex. Both vanA and vanB resistance phenotypes are made penicillins, cephalosporins, carbapenems, and carbacephems.
possible by the products of a group of genes that encode a Enterococci exhibit low levels of resistance to aminoglycosides two-component regulatory system, which causes the resistance and lincosamides [7] . They also have acquired genes to resist to be inducible. Another set of genes encodes a group of envirtually all other known antimicrobial agents, including vancozymes that enable the enterococci to synthesize cell wall premycin [5] .
cursors ending in D-alanine-lactate, instead of D-alanine-D-alaEnterococci are intrinsically resistant to b-lactam agents, as nine, which is the usual vancomycin binding site [3, 10] . The evidenced by the relatively high MICs of most penicillins, affinity of vancomycin (and of teicoplanin) for D-alanineincluding penicillin G and ampicillin. Enterococci also exhibit lactate is 1,000-fold less than that for D-alanine-D-alanine. ''tolerance'' to all agents that inhibit cell wall synthesis, including b-lactam agents and vancomycin. Thus, these antibiotics inhibit but do not effectively kill enterococci at clinically Epidemiology of Vancomycin-Resistant Enterococci achievable concentrations [8] . Although this property is almost universally seen in current clinical isolates of enterococci, it There has been a steady increase in the prevalence of vancomycin-resistant enterococci in the United States during the pretoo is an acquired characteristic [8] .
Increasing resistance to penicillin and ampicillin has been vious 10 years [10, 13] . Now, almost 15% of enterococci in intensive care units of hospitals participating in National Nososeen in recent years in strains of E. faecium [9] . Because of this circumstance, vancomycin was rapidly becoming the agent comial Infections Surveillance surveys exhibit vancomycin resistance. The prevalence of vancomycin resistance in isolates of ''last resort'' for the treatment of infections caused by multidrug-resistant, highly penicillin-resistant E. faecium. It was obtained within United States hospitals, but outside the intensive care units, is also rapidly increasing [10] . About 70% of with considerable consternation, therefore, that the initial reports of vancomycin resistance in enterococci were noted, first the vancomycin-resistant isolates in the United States currently / 9c4c$$my18 04-16-98 11:18:14 cidal UC: CID exhibit the vanA resistance phenotype, and about 25% exhibit cocci [5] . Because resistance to penicillin and ampicillin is currently very infrequent in strains of E. faecalis, these agents the vanB resistance phenotype [14] .
The epidemiology of the spread of vancomycin resistance in can be used to treat infections caused by most strains of vancomycin-resistant E. faecalis. Unfortunately, most of these strains the United States and elsewhere has been extensively studied. There is evidence both for clonal dissemination of resistant in the United States exhibit high levels of aminoglycoside resistance. Therefore, the use of combination therapy for a bacteristrains and for rapid transfer of vancomycin resistance genes among species of enterococci in the hospital [15, 16] . In the cidal effect is often impossible, which is a particular problem in cases of endocarditis and meningitis caused by these organisms. instance of transfer of resistance genes, there are multiple different enterococcal subtypes carrying the same vancomycin resisOne interesting, but on first glance somewhat counterintuitive, approach to the treatment of infections with vancomycintance genes, thereby suggesting a ''plasmid or transposon epidemic.'' There is also considerable heterogeneity in the genetic resistant enterococci is based on the observation that combinations of vancomycin plus ampicillin sometimes exhibit in vitro sequence of vancomycin resistance genes in the United States. This occurrence suggests that these genes are being modified as synergism against vancomycin-resistant enterococci [22] . The mechanism by which this synergy occurs is interesting. It probthey spread among various strains of enterococci [17] .
ably relates to the fact that subinhibitory concentrations of vancomycin induce the synthesis of modified cell wall precurTreating Infections Caused by Vancomycin-Resistant sors ending in D-alanine-lactate. The bacteria, in response, utiEnterococci lize an alternative penicillin-binding protein (PBP) for crosslinking these cell wall precursors. Because it appears that this Generally, the most serious infections due to vancomycinresistant enterococci occur in severely ill immunocompromised PBP is more susceptible to penicillin and ampicillin than is PBP 5, which normally performs this function in enterococci patients. However, enterococcal urinary tract infections may occur in any patient, regardless of the state of debility or immuand is intrinsically resistant to penicillin [23] , the combination might be synergistic. Unfortunately, this phenomenon is inconnocompetence. The major factors predisposing to infection with vancomycin-resistant enterococci include stool carriage of sistent at best. In animal models, colonies resistant to synergism occur with relatively high frequency during therapy [24] . I these organisms by patients or hospital personnel; proximity to patients infected with vancomycin-resistant enterococci;
have personally also observed this phenomenon in human trials of the combination as well (R. C. Moellering, Jr., unpublished hospitalization in an intensive care unit; and, particularly, exposure to antimicrobial agents, including vancomycin, broadobservations).
Teicoplanin has been used to treat selected infections caused spectrum cephalosporins, carbapenems, and antimicrobial agents with activity against anaerobes (including metronidazole by vancomycin-resistant enterococci harboring the vanB resistance phenotype. Again, emergence of resistance during therand clindamycin) [18, 19] . There is also a clear-cut association between the total number of antimicrobial agents received by apy has occurred. If such therapy is to be optimally effective, a second antimicrobial exhibiting in vitro susceptibility, prefera patient and the likelihood of acquisition of infection due to vancomycin-resistant enterococci.
ably an aminoglycoside if possible, should be used. Vancomycin-resistant strains of E. faecium pose even greater As noted above, asymptomatic carriage of vancomycin-resistant enterococci is found frequently on the hands of personnel problems, because many of these strains are also highly resistant to penicillin and ampicillin [5] . Indeed, many of these caring for patients infected with vancomycin-resistant enterococci and may serve as a reservoir for spread of these organorganisms are resistant to all currently available antimicrobial agents. Selected strains are susceptible to tetracyclines, chlorisms. Although a number of infection control measures have been used to try to limit the spread of vancomycin-resistant amphenicol, rifampin, ciprofloxacin, ofloxacin, and/or novobiocin, and there have been anecdotal reports of successes when enterococci, these measures have proven somewhat disappointing and certainly have been far from effective at preventing these agents have been used alone or preferably in combination [5, 25] . Unfortunately, all of these agents are only bacteriostatic the dissemination of vancomycin-resistant enterococci in the hospital [20] . Several small anecdotal series of colonized paand are not particularly useful in treating enterococcal endocarditis or meningitis. tients reported some success with oral bacitracin therapy for eradicating stool carriage of enterococci [21] . Unfortunately, Clinical trials of the investigational drug quinupristin/dalfopristin are now under way. Preliminary results suggest that it there are not enough currently available results to know if this measure will effectively halt the spread of vancomycinis active both in vitro and clinically for infections caused by vancomycin-resistant E. faecium [26] . Unfortunately, this agent resistant enterococci in intensive care units or in other major hospital settings.
is not active against E. faecalis. Thus, its use will likely be limited to infections due to multidrug-resistant E. faecium. Therapy for infections due to vancomycin-resistant enterococci presents real challenges for the clinician. Most isolates Other investigational agents with in vitro activity against vancomycin-resistant enterococci include the oxazolidinones, new of enterococci, whether vancomycin-resistant, remain susceptible to nitrofurantoin, which has been successfully used to treat vancomycin analogues, everninomycin, and some of the new fluoroquinolones with enhanced activity against gram-positive urinary tract infections caused by vancomycin-resistant entero-/ 9c4c$$my18 04-16-98 11:18:14 cidal UC: CID
